Marilena Vrana: Access, Resilience, and Policy Priorities Ahead of IPPC2026
Marilena Vrana, Vice President at the Plasma Protein Therapeutics Association (PPTA) Europe, reposted from on LinkedIn:
”A timely and important contribution from Nikolaj Siersbæk and Copenhagen Economics on the role of plasma-derived medicines in Europe.
This updated report builds on their 2021 analysis and reinforces a critical reality: about a million patients across the continent rely on these life-saving therapies, often with no alternative treatment options.
At the same time, it highlights growing structural challenges, including constrained plasma supply and Europe’s continued reliance on imports.
Addressing these issues will require forward-looking, tailored policy solutions, not a one-size-fits-all approach.
These themes go straight to the heart of what we’ll be discussing at IPPC2026.
I’m particularly looking forward to Nikolaj opening the Congress with a keynote that sets the stage for deeper conversations on Resilience Reach Responsibility, and to engaging with stakeholders across the plasma-PDMP ecosystem in this important conversation on strengthening patient access and resilience in healthcare.
Quoting Copenhagen Economics‘s post:
”The patient need for plasma-derived therapies is increasing.
This trend coincides with escalating concerns over the supply of plasma in the longer term, and a heavy reliance in Europe on plasma imports from the U.S.
We are proud to launch an update of our 2021 publication on the value of plasma-derived therapies in Europe.
We find that:
- The number of patients that can benefit from plasma-derived therapies is significant and some of these diseases have no alternative treatments to plasma-derived therapies
- The plasma-derived therapies industry supports the European economy both directly and through the cascading effects across the broader supply chain
- The plasma-derived therapies industry in Europe is constrained due to the scarcity of donated human plasma, and while some of the market issues surrounding the industry could be alleviated through more effective utilisation of plasma, a re-evaluation of donation schemes would be needed to secure the European plasma supply
Reach out to Nikolaj Siersbæk to hear more, and read the full report”
Stay updated with Hemostasis Today.
-
Mar 19, 2026, 16:46Connie Montgomery: Celebrating Heroes of the Bleeding Disorders Community
-
Mar 19, 2026, 16:44Anita Brikman: Advancing Plasma Availability and Access to Plasma-Derived Therapies in India
-
Mar 19, 2026, 16:41Sinju Thomas: Early Initiation and Collaboration are Critical in Stem Cell Collection for Haemoglobinopathies
-
Mar 19, 2026, 16:34Aloke Finn: The Role of Silent Plaque Rupture in Atherosclerotic Disease Evolution
-
Mar 19, 2026, 16:31How Traumatic Pain Memories May Influence the Way Pain Is Felt in the Present – EAHAD
-
Mar 19, 2026, 16:29Simon Senanu: Iron Deficiency Anemia vs Anemia of Chronic Disease
-
Mar 19, 2026, 16:24Rustam Al Shahi Salman: An Untapped Potential for Biomarker Discovery In Various Contexts for Stroke
-
Mar 19, 2026, 15:43Samwel Mikaye: Understanding D-Dimer in Clinical Practice
-
Mar 19, 2026, 15:34Kanishk Kumar: Wiskott-Aldrich Syndrome Pipeline Outlook Report 2026